Solving the antidepressant efficacy question: effect sizes in major depressive disorder - PubMed (original) (raw)
Review
Solving the antidepressant efficacy question: effect sizes in major depressive disorder
Paul A Vöhringer et al. Clin Ther. 2011 Dec.
Abstract
Background: Numerous reviews and meta-analyses of the antidepressant literature in major depressive disorders (MDD), both acute and maintenance, have been published, some claiming that antidepressants are mostly ineffective and others that they are mostly effective, in either acute or maintenance treatment.
Objective: The aims of this study were to review and critique the latest and most notable antidepressant MDD studies and to conduct our own reanalysis of the US Food and Drug Administration database studies specifically analyzed by Kirsch et al.
Methods: We gathered effect estimates of each MDD study. In our reanalysis of the acute depression studies, we corrected analyses for a statistical floor effect so that relative (instead of absolute) effect size differences were calculated. We also critiqued a recent meta-analysis of the maintenance treatment literature.
Results: Our reanalysis showed that antidepressant benefit is seen not only in severe depression but also in moderate depression and confirmed a lack of benefit for antidepressants over placebo in mild depression. Relative antidepressant versus placebo benefit increased linearly from 5% in mild depression to 12% in moderate depression to 16% in severe depression. The claim that antidepressants are completely ineffective, or even harmful, in maintenance treatment studies involves unawareness of the enriched design effect, which, in that analysis, was used to analyze placebo efficacy. The same problem exists for the standard interpretation of those studies, although they do not prove antidepressant efficacy either, since they are biased in favor of antidepressants.
Conclusions: In sum, we conclude that antidepressants are effective in acute depressive episodes that are moderate to severe but are not effective in mild depression. Except for the mildest depressive episodes, correction for the statistical floor effect proves that antidepressants are effective acutely. These considerations only apply to acute depression, however. For maintenance, the long-term efficacy of antidepressants is unproven, but the data do not support the conclusion that they are harmful.
Copyright © 2011 Elsevier HS Journals, Inc. All rights reserved.
Similar articles
- Can people with nonsevere major depression benefit from antidepressant medication?
Stewart JA, Deliyannides DA, Hellerstein DJ, McGrath PJ, Stewart JW. Stewart JA, et al. J Clin Psychiatry. 2012 Apr;73(4):518-25. doi: 10.4088/JCP.10m06760. Epub 2011 Dec 27. J Clin Psychiatry. 2012. PMID: 22226407 - Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Cipriani A, et al. Lancet. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21. Lancet. 2018. PMID: 29477251 Free PMC article. Review. - Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA, Chen YF, Yang Y, Yang P, Laughren TP. Khin NA, et al. J Clin Psychiatry. 2011 Apr;72(4):464-72. doi: 10.4088/JCP.10m06191. J Clin Psychiatry. 2011. PMID: 21527123 - Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.
Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas GI. Freeman MP, et al. J Clin Psychiatry. 2010 Jun;71(6):682-8. doi: 10.4088/JCP.10r05976blu. J Clin Psychiatry. 2010. PMID: 20573327 - Efficacy and tolerability of antidepressants for sub-threshold depression and for mild major depressive disorder.
Cameron IM, Reid IC, MacGillivray SA. Cameron IM, et al. J Affect Disord. 2014 Sep;166:48-58. doi: 10.1016/j.jad.2014.04.078. Epub 2014 May 9. J Affect Disord. 2014. PMID: 25012410 Review.
Cited by
- The Impact of _N_-acetylcysteine on Major Depression: Qualitative Observation and Mixed Methods Analysis of Participant Change during a 12-week Randomised Controlled Trial.
Russell SE, Skvarc DR, Mohebbi M, Camfield D, Byrne LK, Turner A, Ashton MM, Berk M, Dodd S, Malhi GS, Cotton SM, Bush AI, Dean OM. Russell SE, et al. Clin Psychopharmacol Neurosci. 2023 May 30;21(2):320-331. doi: 10.9758/cpn.2023.21.2.320. Clin Psychopharmacol Neurosci. 2023. PMID: 37119225 Free PMC article. - Community-Delivered Heated Hatha Yoga as a Treatment for Depressive Symptoms: An Uncontrolled Pilot Study.
Nyer M, Hopkins LB, Farabaugh A, Nauphal M, Parkin S, McKee MM, Miller KK, Streeter C, Uebelacker LA, Fava M, Alpert JE, Pedrelli P, Mischoulon D. Nyer M, et al. J Altern Complement Med. 2019 Aug;25(8):814-823. doi: 10.1089/acm.2018.0365. Epub 2019 Jul 10. J Altern Complement Med. 2019. PMID: 31290694 Free PMC article. - Functional near-infrared spectroscopy-based diagnosis support system for distinguishing between mild and severe depression using machine learning approaches.
Huang Z, Liu M, Yang H, Wang M, Zhao Y, Han X, Chen H, Feng Y. Huang Z, et al. Neurophotonics. 2024 Apr;11(2):025001. doi: 10.1117/1.NPh.11.2.025001. Epub 2024 Apr 24. Neurophotonics. 2024. PMID: 38660382 Free PMC article. - A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression.
Romijn AR, Rucklidge JJ, Kuijer RG, Frampton C. Romijn AR, et al. Aust N Z J Psychiatry. 2017 Aug;51(8):810-821. doi: 10.1177/0004867416686694. Epub 2017 Jan 10. Aust N Z J Psychiatry. 2017. PMID: 28068788 Free PMC article. Clinical Trial. - Athanasios Koukopoulos' Psychiatry: The Primacy of Mania and the Limits of Antidepressants.
Ghaemi SN, Vohringer PA. Ghaemi SN, et al. Curr Neuropharmacol. 2017 Apr;15(3):402-408. doi: 10.2174/1570159X14666160621113432. Curr Neuropharmacol. 2017. PMID: 28503112 Free PMC article. Review.
References
- Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–17. - PubMed
- Geddes JR, et al. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev. 2000;(2):CD001851. - PubMed
- Kornstein SG, K.J., Ahmed S, Thase M, Friedman ES, Dunlop BW, Yan B, Pedersen R, Ninan PT, Li T, Keller M. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75–225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study. International clinical psychopharmacology. 2008;23(6):357–363. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K23 MH064189-01/MH/NIMH NIH HHS/United States
- 5R01MH078060/MH/NIMH NIH HHS/United States
- K23 MH064189/MH/NIMH NIH HHS/United States
- R01 MH078060/MH/NIMH NIH HHS/United States
- R01 MH078060-01A1/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical